These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 29205425)

  • 21. Testing for qualitative heterogeneity: An application to composite endpoints in survival analysis.
    Oulhaj A; El Ghouch A; Holman RR
    Stat Methods Med Res; 2019 Jan; 28(1):151-169. PubMed ID: 28670972
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Consistency-ensured parametric tests for critical events of composite endpoints.
    Huque MF; Alosh M; Guerra M
    J Biopharm Stat; 2018; 28(1):82-98. PubMed ID: 29144871
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiplicity adjustment for composite binary endpoints.
    Rauch G; Kieser M
    Methods Inf Med; 2012; 51(4):309-17. PubMed ID: 22525969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simultaneous inference of a binary composite endpoint and its components.
    Große Ruse M; Ritz C; Hothorn LA
    J Biopharm Stat; 2017; 27(1):56-69. PubMed ID: 26881805
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A generalized analytic solution to the win ratio to analyze a composite endpoint considering the clinical importance order among components.
    Dong G; Li D; Ballerstedt S; Vandemeulebroecke M
    Pharm Stat; 2016 Sep; 15(5):430-7. PubMed ID: 27485522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Weighted analysis of composite endpoints with simultaneous inference for flexible weight constraints.
    Duc AN; Wolbers M
    Stat Med; 2017 Feb; 36(3):442-454. PubMed ID: 27782312
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The stratified win ratio.
    Dong G; Qiu J; Wang D; Vandemeulebroecke M
    J Biopharm Stat; 2018; 28(4):778-796. PubMed ID: 29172988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generalized pairwise comparison methods to analyze (non)prioritized composite endpoints.
    Verbeeck J; Spitzer E; de Vries T; van Es GA; Anderson WN; Van Mieghem NM; Leon MB; Molenberghs G; Tijssen J
    Stat Med; 2019 Dec; 38(30):5641-5656. PubMed ID: 31659790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect.
    Royston P; Parmar MK
    Trials; 2014 Aug; 15():314. PubMed ID: 25098243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Opportunities and challenges of clinical trials in cardiology using composite primary endpoints.
    Rauch G; Rauch B; Schüler S; Kieser M
    World J Cardiol; 2015 Jan; 7(1):1-5. PubMed ID: 25632312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Investigations of methods for multiple time-to-event endpoints: A chronic myeloid leukemia data analysis.
    Wu H; Hou Y; Chen Z
    J Eval Clin Pract; 2023 Feb; 29(1):211-217. PubMed ID: 35945813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Noninferiority hypotheses and choice of noninferiority margin.
    Ng TH
    Stat Med; 2008 Nov; 27(26):5392-406. PubMed ID: 18680173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of a binary composite endpoint with missing data in components.
    Quan H; Zhang D; Zhang J; Devlamynck L
    Stat Med; 2007 Nov; 26(26):4703-18. PubMed ID: 17431851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of composite endpoints in clinical trials.
    Sankoh AJ; Li H; D'Agostino RB
    Stat Med; 2014 Nov; 33(27):4709-14. PubMed ID: 24833282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
    Schmidt R; Burkhardt B; Faldum A
    Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Calculating power for the Finkelstein and Schoenfeld test statistic for a composite endpoint with two components.
    Zhou TJ; LaValley MP; Nelson KP; Cabral HJ; Massaro JM
    Stat Med; 2022 Jul; 41(17):3321-3335. PubMed ID: 35486817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Familywise error for multiple time-to-event endpoints in a group sequential design.
    Thomsen HF; Lausvig NL; Pipper CB; Andersen S; Damgaard LH; Emerson SS; Ravn H
    Stat Med; 2024 Aug; 43(18):3417-3431. PubMed ID: 38852994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of proportions for composite endpoints with missing components.
    Li X; Caffo BS
    J Biopharm Stat; 2011 Mar; 21(2):271-81. PubMed ID: 21391001
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Flexible estimation of differences in treatment-specific recurrent event means in the presence of a terminating event.
    Pan Q; Schaubel DE
    Biometrics; 2009 Sep; 65(3):753-61. PubMed ID: 19053997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficient estimation of the distribution of time to composite endpoint when some endpoints are only partially observed.
    Daniel RM; Tsiatis AA
    Lifetime Data Anal; 2013 Oct; 19(4):513-46. PubMed ID: 23722304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.